相关临床试验
518
76 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1859
进行中（未招募）
35
6.8%
已完成
280
54.0%
Enrolling By Invitation
4
0.8%
尚未招募
37
7.1%
招募中
95
18.3%
终止
39
7.5%
Unknown
10
1.9%
撤回
18
3.5%
暂无批准数据
- Excelsior Sciences raised $95 million in Series A funding to develop proprietary "smart bloccs" technology that enables machines to perform chemistry and AI to guide closed-loop drug discovery. - The company's automated synthesis platform aims to accelerate drug discovery timelines by rapidly producing and testing compounds while generating rich data for AI algorithms. - The funding addresses pharmaceutical industry pressure to reshore drug discovery and manufacturing capabilities, with the industry committing over $250 billion to reduce strategic vulnerabilities. - Excelsior's technology bridges the gap between AI drug design theory and practical chemical synthesis, potentially transforming both therapeutics and materials science sectors.
- Researchers at the University of Illinois have developed a macroporous hydrogel-based mRNA cancer vaccine platform that actively recruits dendritic cells to improve vaccine efficiency. - The innovative approach uses chemokines within the hydrogel to draw dendritic cells to the injection site, dramatically increasing the probability of mRNA-dendritic cell interactions compared to conventional passive diffusion methods. - Preclinical studies demonstrate that this materials-enabled strategy leads to enhanced T-cell activation and stronger antitumor immune responses. - The research, led by Associate Professor Hua Wang and doctoral researcher Jiadiao Zhou, addresses a critical limitation in mRNA cancer vaccines where extremely low efficiency of antigen processing by immune cells has been a major hurdle.
- Professor Sarfaraz K. Niazi has secured the first-ever FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars, fundamentally redefining biological drug development and approval processes. - The breakthrough decision is expected to reduce biosimilar development costs by over 90% and accelerate approval timelines by more than 70%, making biological medicines more accessible to patients worldwide. - Niazi's Stelara biosimilar application will be the first filed with the FDA without requiring clinical testing, establishing a precedent-setting regulatory pathway. - The regulatory shift empowers smaller companies to enter the biosimilar market and aligns FDA practices with the European Medicines Agency and UK's MHRA approaches.
- University of Illinois researchers have successfully applied metabolic glycan labeling to platelets for the first time, overcoming the challenge of engineering these nucleus-free cell fragments. - The novel chemical approach allows scientists to attach tags to platelet surfaces within hours, both in laboratory settings and living organisms, creating potential vehicles for targeted drug delivery. - This breakthrough could revolutionize treatment for cancer, immune diseases, and blood clotting disorders, with the added benefit that platelets' short half-life ensures drugs clear from the body within days.
